

#### COMMENTARY

# Obstructive sleep apnea and atrial fibrillation: we need to go step by step

Commentary on Mohammadieh AM, Sutherland K, Kanagaratnam LB, Whalley DW, Gillett MJ, Cistulli PA. Clinical screening tools for obstructive sleep apnea in a population with atrial fibrillation: a diagnostic accuracy trial. *J Clin Sleep Med*. 2021;17(5):1015–1024. doi:10.5664/jcsm.9098

Manuel Sánchez-de-la-Torre, PhD1,2; Chi-Hang Lee, MD3; Ferran Barbé, MD1,4

<sup>1</sup>Group of Precision Medicine in Chronic Diseases, Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; <sup>2</sup>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; <sup>3</sup>Department of Cardiology, National University Heart Center, Singapore; ⁴Group of Translational Research in Respiratory Medicine, Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain

Obstructive sleep apnea (OSA) is a chronic disease that affects more than 20% of the global adult population. Despite its high prevalence, OSA remains an underdiagnosed disease. In clinical practice, OSA is usually suspected in patients presenting with excessive daytime sleepiness. However, it has been shown that half of patients with moderate-to-severe OSA are asymptomatic, rendering this approach insensitive. As a result, the deleterious consequences of OSA are frequently unrecognized among asymptomatic individuals.

Beyond sleepiness, OSA is a prevalent cardiovascular risk factor, present in half of patients with hypertension.<sup>2</sup> The prevalence is even higher (up to 70%) in those with hypertension and concomitant high-risk profiles, such as resistant hypertension.<sup>3</sup> Although the benefit of continuous positive airway pressure therapy in symptom relief has been well established, the anticipated benefits in reducing the risk incidence of major adverse cardiovascular events have remained controversial. This dilemma makes the value of OSA screening in asymptomatic individuals questionable. Although there has been some progress in identifying patients with OSA who are at high risk of developing cardiovascular events,<sup>4</sup> there is still a long way to go before the therapeutic benefits of continuous positive airway pressure can be solidly established.

In recent years, the relationship between atrial fibrillation (AF) and OSA has been explored. A high prevalence of OSA has been reported in patients with AF.<sup>5</sup> The Sleep Heart Health Study found a 4-fold increase in the prevalence of AF in patients with OSA. One-third of participants had arrhythmia documented during sleep.<sup>6</sup> Likewise, the Olmsted County study found that OSA and its severity strongly predicted the 5-year incidence of AF.<sup>7</sup> Atrial stretch, neurohumoral activation, and chronic concomitant conditions (hypertension, metabolic syndrome, and obesity) create a progressive structural atrial substrate remodeling in patients with OSA. These, together with transient apnea—associated electrophysiological changes, contribute to the reentry substrate for AF that creates a complex and dynamic arrhythmogenic substrate in the atrium during

sleep.<sup>8</sup> Apart from being associated with a high prevalence of AF, untreated OSA reduces the effectiveness of AF treatment.<sup>8</sup> Patients with AF who have concomitant OSA, compared with those without, show a lower response rate to antiarrhythmic drug therapy.<sup>9</sup> Similarly, prospective studies have shown that patients with OSA, compared to those without, have a lower success rate in maintaining sinus rhythm (ie, a higher recurrence of AF) after an initial successful cardioversion and catheter ablation.<sup>10,11</sup> Meta-analyses of observational studies with a total of approximately 1,000 patients have shown that patients with OSA have a 31% higher risk of AF recurrence after pulmonary vein isolation (a catheter-based intervention procedure for rhythm control).<sup>12,13</sup>

Screening for and treatment of OSA in the management of AF is endorsed by the 2020 European Society of Cardiology guidelines on AF. <sup>14</sup> It is conceivable that the potential benefits of OSA treatment in AF recurrence will need to be evaluated by clinical trials. Likewise, given the high prevalence of AF, the roles of simple and accessible diagnostic methods will need to be evaluated. In this regard, the report by Mohammadieh et al <sup>15</sup> in this issue of the *Journal of Clinical Sleep Medicine* is relevant and timely. In their well-designed study, the authors explored the validity of several commonly used OSA screening tools in patients who were admitted to the emergency department with AF or were scheduled to undergo pulmonary vein isolation.

Using the gold-standard in-laboratory polysomnography as a reference, the authors found that the portable home sleep apnea test showed the highest diagnostic accuracy at all levels of OSA severity, with the area under the curve reaching 0.9. More important, testing with the home sleep apnea test was perceived by patients as more comfortable, more convenient, and more closely matched to their usual sleep pattern than in-laboratory polysomnography. Because the home sleep apnea test is a sophisticated monitoring device, it is not surprising that the other OSA screening tools (snoring, obesity, airway crowding, Epworth Sleepiness Scale, STOP-BANG questionnaire, and Berlin questionnaire) were found to be inferior in diagnostic accuracy.

It is also worthwhile to note that patients with cardiovascular disease, even with concomitant OSA, generally do not experience daytime sleepiness. In Mohammadieh et al,15 the Epworth Sleepiness Scale score was only marginally higher in the OSA group (apnea-hypopnea index  $\geq 15$  events/h) than in the non-OSA group (apnea-hypopnea index < 15 events/h; 6.9 vs 5.7). Although the authors did not report the prevalence of an Epworth Sleepiness Scale score > 10, it should conceivably be very low. These results again raise pertinent but unresolved issues: (1) the cardiovascular implications of untreated OSA beyond AF recurrence, and (2) the benefits of OSA therapy in improving cardiovascular outcomes in patients with AF. Although recent clinical trials have not shown a positive effect of continuous positive airway pressure in patients with coronary artery disease, 16-18 these studies carried inherent limitations as previously addressed.<sup>19</sup> AF, a cardiac electrophysiological disorder, is fundamentally different from coronary artery disease. The neutral results of the trials on coronary artery disease cannot be applied to AF. Currently, data showing the benefits of OSA treatment in mitigating the risk of AF recurrence after cardioversion and ablative procedures are only based on observational studies. 10,11

In considering all of the above information, we have to go step by step: Once the high prevalence of OSA in the AF population has been reported, the positive effect of OSA treatment in this population needs to be confirmed. Only after this confirmation, regardless of the presence or absence of OSA symptoms, can the need to actively screen for the presence of this disease in patients with AF be claimed, noting the therapeutic approach of OSA as an effective response to treat the risks of AF.

#### **CITATION**

Sánchez-de-la-Torre M, Lee C-H, Barbé F. Obstructive sleep apnea and atrial fibrillation: we need to go step by step. *J Clin Sleep Med.* 2021;17(5):869–870.

## **REFERENCES**

- Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med*. 2015;3(4):310–318.
- Javaheri S, Barbé F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017; 69(7):841–858.
- Navarro-Soriano C, Martínez-García MA, Torres G, et al. Long-term effect of CPAP treatment on cardiovascular events in patients with resistant hypertension and sleep apnea. Data from the HIPARCO-2 study [published online ahead of print 2020 Feb 3]. Arch Bronconeumol.
- Azarbarzin A, Sands SA, Stone KL, et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Eur Heart J. 2019;40(14):1149–1157.
- Stevenson IH, Teichtahl H, Cunnington D, Ciavarella S, Gordon I, Kalman JM. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. *Eur Heart J*. 2008;29(13):1662–1669.

- Mehra R, Benjamin EJ, Shahar E, et al. Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173(8):910–916.
- Kendzerska T, Gershon AS, Atzema C, et al. Sleep apnea increases the risk of new hospitalized atrial fibrillation: a historical cohort study. *Chest.* 2018;154(6): 1330–1339.
- Linz D, McEvoy RD, Cowie MR, et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018;3(6):532–540.
- Monahan K, Brewster J, Wang L, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110(3):369–372.
- Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107(20):2589–2594.
- Bavishi AA, Kaplan RM, Peigh G, et al. Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. *Pacing Clin Electrophysiol*. 2019;42(6):694–704.
- Shukla A, Aizer A, Holmes D, et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. *JACC Clin Electrophysiol*. 2015; 1(1–2):41–51.
- Youssef I, Kamran H, Yacoub M, et al. Obstructive sleep apnea as a risk factor for atrial fibrillation: a meta-analysis. J Sleep Disord Ther. 2018;7(1):282.
- Hindricks G, Potpara T, Dagres N, et al.ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
- Mohammadieh AM, Sutherland K, Kanagaratnam LB, Whalley DW, Gillett MJ, Cistulli PA. Clinical screening tools for obstructive sleep apnea in a population with atrial fibrillation: a diagnostic accuracy trial. J Clin Sleep Med. 2021;17(5): 1015–1024.
- McEvoy RD, Antic NA, Heeley E, et al.SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919–931.
- Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Respir Med.* 2020;8(4):359–367.
- Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized controlled trial. Am J Respir Crit Care Med. 2016;194(5):613–620.
- Pack AI, Magalang UJ, Singh B, Kuna ST, Keenan BT, Maislin G. Randomized clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and overcoming bias. Sleep. 2021;44(2):zsaa229.

## SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication March 10, 2021 Submitted in final revised form March 10, 2021 Accepted for publication March 10, 2021

Address correspondence to: Ferran Barbé, MD, Translational Research in Respiratory Medicine, Hospital Universitario Arnau de Vilanova-Santa María, IRB Lleida, CIBERes, Avenida Rovira Roure 80, 25198, Lleida, Spain; Email: febarbe.lleida.ics@gencat.cat

#### **DISCLOSURE STATEMENT**

All authors have seen and approved the manuscript. This study was funded by Instituto de Salud Carlos III (ISCIII) (PI18/00449, PI19/00907) and co-funded by Fondo Europeo de Desarrollo Regional, "Una manera de hacer Europa." The authors report no conflicts of interest.